# Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

> **NCT03406078** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 150 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Tezepelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03406078
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2020-09-25
- **Final completion:** 2020-09-25
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2021-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406078, "Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03406078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*